EUVIMEDEUVIMED entdecken
Crossref

Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells

Dongxue Zhang, Xiaoyu Shi, Weimin Zheng, Xian Zhang, Yun Chen iD

PROTEOMICS – Clinical Applications · 2024

DOI: 10.1002/prca.202300061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2024. Verfasst von Dongxue Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, SEU-NJMU-CPU Cooperation Project, Open Foundation of State Key Laboratory of Reproductive Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This research aimed to find potential HER2 mutations that would have an impact on breast cancer and investigate the underlying mechanism. Experimental design This study first investigated 238 pairs of breast cancer and para‐cancerous tissue samples from patients on the targeted next‐generation sequencing (tNGS) platform. CCK‐8 and clone formation assay were used to investigate whether the mutation exerts proliferative effects on breast cancer cells. In addition, mass spectrometry‐based comparative proteomic and phosphoproteomic analyses of the mutation types and wild types of MCF‐7 cell lines were carried out.

Results

Among the identified mutations, a new mutation HER2 L796P promoted the proliferation of breast cancer cells and had resistance to lapatinib using CCK‐8 cell proliferation assay and clone formation assay. The bioinformatic analysis showed that RAS family proteins and ERK phosphorylated proteins significantly increased in the L796P mutant cells. The Gene Ontology (GO) analysis revealed that L796P mutation affected the function of breast cancer at the level of upstream genes in the MAPK and PI3K‐AKT‐TOR pathways. Conclusions and clinical relevance This study demonstrated that a rare mutation HER2 L796P could be a potential therapeutic target for the clinical management of breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFemaleHumansCell Line, TumorDrug Resistance, NeoplasmMutationMutation, MissensePhosphatidylinositol 3-KinasesProteomicsQuinazolinesErb-b2 Receptor Tyrosine KinasesSincalide

Stichwörter der Autor:innen

HER2 L796Pbreast cancermass spectrometrymulti-omics techniqueprotein mutation

Substanzen

Phosphatidylinositol 3-KinasesQuinazolinesErb-b2 Receptor Tyrosine KinasesSincalideERBB2 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Nanjing Medical University, Nanjing, China.
  • State Key Laboratory of Reproductive Medicine and Offspring Health, Nanjing, China.
  • Key Laboratory of Cardiovascular & Cerebrovascular Medicine, Nanjing, China.

ORCID-Profile: Yun Chen

Förderung

  • National Natural Science Foundation of China
  • SEU-NJMU-CPU Cooperation Project
  • Open Foundation of State Key Laboratory of Reproductive Medicine
  • Science and Technology Development Fund of NJMU
  • Primary Research & Development Plan of Jiangsu Province

Zitieren

APA

Zhang, D., Shi, X., Zheng, W., Zhang, X., & Chen, Y. (2024). Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.202300061

Vancouver

Zhang D, Shi X, Zheng W, Zhang X, Chen Y. Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells. PROTEOMICS – Clinical Applications. 2024. doi:10.1002/prca.202300061

BibTeX
@article{Zhang2024,
  author = {Zhang, Dongxue and Shi, Xiaoyu and Zheng, Weimin and Zhang, Xian and Chen, Yun},
  title = {Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2024},
  doi = {10.1002/prca.202300061}
}
Kostenlos starten →